U.S., Feb. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07413679) titled 'Long-term Safety of Danicopan: IPIG Registry-based Cohort Study' on Feb. 10.
Brief Summary: This is a noninterventional cohort study using primary and secondary data from the International PNH Interest Group (IPIG) PNH registry. It is designed to characterize the long-term safety and tolerability of danicopan as add-on therapy to eculizumab or ravulizumab in adult participants with PNH.
Study Start Date: Aug. 18, 2025
Study Type: OBSERVATIONAL
Condition:
Paroxysmal Nocturnal Hemoglobinuria
PNH
Intervention:
DRUG: Danicopan
Participants will receive Danicopan as an add-on therapy.
Recruitment Status: ACTIVE_NOT_RECRUITING
Sp...